Abstract
This article describes the State-supported University of California AIDS research award program and its major accomplishments. It shows how a partnership between a University and a State resulted in the formation of a successful, efficient, and cost-effective AIDS research award program. This program provides funds for rapid testing of investigator-initiated meritorious research ideas, new drugs, and treatment modalities. Funds were also utilized to establish three AIDS Clinical Research Centers, which evolved into regional consortia that coordinate trials of new drugs and other modalities. This program succeeded in involving investigators whose efforts have led to excellent medical care, advanced technologies, and new drugs for treating AIDS and AIDS-related diseases. The University remains committed to continuing support of all areas of AIDS research, emphasizing drug and vaccine development, pediatric AIDS, and AIDS prevention studies in groups at high risk for HIV infection.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
University of California, Universitywide AIDS Research Program: Guide to Policies and Procedures. Revised July 1990
Rowe M, Keintz K: National Survey of State Funding for AIDS. The George Washington University, Intergovernmental AIDS Report 2:1–12, 1989
Levy JA, Hoffman AD, Kramer SM,et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225:840–842, 1984
Luciw PA, Potter SJ, Steimer K, Dina D, Levy JA: Molecular cloning of AIDS-associated retrovirus. Nature 312:760–763, 1984
Levy JA, Evans LA, Tateno M, Walker C, Homsy J, Cheng-Mayer C.: Biologic, serologic and molecular differences among human immunodeficiency viruses (HIV).In Human Retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy, Alan R. Liss, New York, 1988, pp 91–100
Levy JA, Mitra G, Mozen MM: Recovery and inactivation of infectious retroviruses from factor VIII concentrates. Lancet 2:722–725, 1984
Cheng-Mayer C, Iannello P, Shaw K, Luciw PA, Levy JA: Differential effect ofnef on HIV replication: Implications for viral pathogenesis in the host. Science 246:1629–1632, 1989
Garcia JA, Harrich D, Soultanakis E, Wu F, Mitsuyasu R, Gaynor RB: Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J 9:765–778, 1989
Jones KA, Luciw PA, Duchange N: Structural arrangements of transcription control domains within the 5′-untranslated leader regions of the HIV-1 and HIV-2 promotors. Genes Dev 2:1101–1114, 1988
Peterlin BM, Luciw PA: Molecular biology of HIV. AIDS 1988;2 (Suppl 1):S29-S40.
Gardner M, Jennings M, Carlson JR,et al. Postexposure immunotherapy of simian immunodeficiency virus (SIV) infected rhesus with an SIV immunogen. J Med Primatol. 18:321–328, 1989
Gardner M, Luciw PA, Marx P,et al. An approach to immunotherapy of simian immunodeficiency virus-infected rhesus with an inactivated whole SIV immunogen.In Vaccines 89. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
Marthas ML, Banapour B, Sutjipto S,et al. Rhesus macaques inoculated with molecularly cloned simian immunodeficiency virus. J Med Primatol, 18:311–319, 1989
Morrow WJW, Homsy J, Eichberg JW,et al. Long-term observation of baboons, rhesus monkeys, and chimpanzees inoculated with HIV and given periodic immunosuppressive treatment. AIDS Res Human Retrovirus 5:233–245, 1989
Gardner MB, McGraw T, Luciw P, Carlson J: SIV vaccine protection of rhesus macaques. Sixth Int Conf AIDS Abstr 1:205, 1990
Chaisson RE, Allain JP, Leuther M, Volberding PA: Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. N Engl J Med 315:1610–1612, 1986
Volberding PA, Stephen WL, Mattew AK,et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 322:941–949, 1990
Fischel MA, Richman DD, Grieco DM,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317:185–191, 1987
Spector SA, Kennedy C, McCutchan JA,et al. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. J Infect Dis 159:822–828, 1989
Conte JE Jr, Upton RA, Phelps RT, Wofsy CB, Zurlinden E, Lin ET: Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J Infect Dis 154:923–929, 1986
Debs RJ, Blumenfeld W, Brunette EN,et al. Successful treatment with aerosolized pentamidine ofPneumocystis carinii pneumonia in rats. Antimicrob Agents Chemother 31:37–41, 1987
Montgomery AB, Debs RJ, Luce JM, Corkery KJ, Turner J, Hopewell PC: Aerosolized pentamidine as second line therapy in patients with AIDS andPneumocystis carinii pneumonia. Chest 95:747–750, 1989
McCutchan JA, Tiles JG, Leedom JM, Stevens DA: California Collaborative Treatment Group—The first four years. Universitywide AIDS Research Program and Task Force on AIDS. Annual Meeting of Principal Investigators. San Diego, CA, March 1990
Boyer C, Shafer MA: Evaluation of a high school-based education and skills training intervention for prevention of AIDS and STDs. Sixth Int Conf AIDS, San Francisco, CA, Abstr 3:107, 1990
Cohen JB, Hauer LB, Wofsy CB: Women and IV drugs: Parenteral and heterosexual transmission of human immunodeficiency virus. J Drug Issues 19:39–56, 1989
Flynn N, Jain S, Bailey V, Anderson R, Sweha A: IVDU: More resistant to changing their sexual practices than their drug practices. Universitywide AIDS Research Program and Task Force on AIDS. Annual Meeting of Principal Investigators, San Diego, CA, March 1990
Coates TJ, McKusick L, Kuno R, Stites DP: Stress reduction training changed number of sexual partners but not immune function in men with HIV. Am J Public Health 79:885–887, 1989
Cooke M, Koenig B, Beery N, Falkman S: Which physicians will provide AIDS Care? Sixth Int Congr AIDS, San Francisco, CA, Abstr 3:108, 1990
Levy JA, Hollander H, Shimabukuro JM, Mills J, Kaminsky L: Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet 2:586–588, 1985
Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG: AIDS retrovirus induced cytopathology: Giant cell formation and involvement of CD4 antigen. Science 232:1123–1127, 1986
Levy JA, Shimabukuro J, McHugh T,et al. AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells. Virology 147:441–448, 1985
Lee Mr, Ho DD, Gurney ME: Functional interaction and partial homology between human immunodeficiency virus and neuroleukin. Science 237:1047–1051, 1987
Peterlin BM, Calman AF, Kao S-Y, Selby M, Tong-Starksen S, Luciw PA: Activation andtrans-activation of HIV-1.In The Control of Human Retrovirus Gene Expression, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1988, pp 45–57
Cheng-Mayer C, Seto D, Tateno M, Levy J: Biologic features of HIV-1 that correlates with virulence in the host. Science 240:80–82, 1988
Richman DD, Fischl MA, Grieco MH,et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317:192–197, 1987
Bozzette SA, Sattler FR, Chiu J,et al. Early adjunctive corticosteroids prevent respiratory failure and death in patients with AIDS andPneumocystis carinii pneumonia. N Engl J Med 323:1451–1457, 1990
Chiu J, Nussbaum J, Bozzette S,et al. Treatment of disseminatedMycobacterium avium complex in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med 113:358–361, 1990
Groopman JE, Mitsuyasu RT, DeLeo M,et al. Effect of recombinant human granulocyte-macrophage-colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317:593–598, 1987
Miles T, Mitsuyasu RT, Fink N,et al.: Recombinant G-CSF and recombinant erythropoietin may abrogate the neutropenia and anemia of AIDS and may allow for resumption of AZT. Fifth International Congress on AIDS, Montreal, Canada 1989, Abstract, p 550
Miles SA, Wang HJ, Cortes E, Carden J, Marcus S, Mitsuyasu RT: Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 112:582–589, 1990
Groopman JE, Gottlieb MS, Goodman J,et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma. N Engl J Med 100:1071–1076, 1984
Langsam J: AIDS Specimen Bank. US Dept Health Hum Serv Res Resources Rep 13:13–14, 1989
Carlson JR, Yee J, Watson-Williams EJ,et al. Rapid, easy, and economical screening test for antibodies to human immunodeficiency virus. Lancet 2:361–362, 1987
Ho DD, Moudgil T, Alam M: Quantitation of an immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 321:1621–1625, 1989
Bacchetti P, Osmond D, Chaisson RE,et al. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis 157:1044–1047, 1988
Siegel D, Krasnovsky F, Lazarus N,et al.: Preventing AIDS in high risk adolescents. Universitywide Task Force on AIDS. Annual Meeting of Principal Investigators, San Diego, CA, March 1989
Padian N, Shiboski S, Vranizan K, Moore L, Jewell N, Moss AR: Heterosexual transmission of AIDS. Universitywide AIDS Research Program and Task Force on AIDS. Annual Meeting of Principal Investigators, San Diego, CA, March 1990
Scitovsky AA, Cline M, Lee PR: Medical care costs of patients with AIDS in San Francisco. JAMA 256:3103–3106, 1986
Gerberding JL, Bryant-Le Blanc CE, Nelson K,et al. Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. J Infect Dis 156:1–8, 1987
Kuhls TL, Viker S, Parris NB, Garakian A, Sullivan-Bolyai J, Cherry JD: Occupational risk of HIV, HBV and HSV-2 infections in healthcare personnel caring for AIDS patients. Am J Public Health 77:1306–1309, 1987
Moss AR, Bacchetti P, Osmond D,et al. Seropositivity for HIV and the development of AIDS or AIDS-related condition: Three year follow up of the San Francisco General Hospital cohort. BMJ 296:745–750, 1988
University of California, Universitywide AIDS Research Program—Supported by the State of California. Program Overview (1983–89) and Annual Progress Report, FY 1988–89, January 1990
Cordes C: End to Special status of AIDS studies at NIH is sought. Chron High Educ 36:A1, 1990
California AIDS Update. Sacramento, CA, State of California, Department of Health Services—Offices of AIDS, 3:72, July 1990
HIV/AIDS Surveillance. Atlanta, GA, Centers for Disease Control, 9, July 1990
Lane SR, Levine RN: Caring for homeless people with HIV disease. Focus 5:1–2, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Das, N.K., Hopper, C.L., Jencks, M. et al. A university of California state-supported AIDS research award program—A unique state and university partnership in AIDS research. J Clin Immunol 11, 65–73 (1991). https://doi.org/10.1007/BF00917742
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00917742